Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Yunkai, Yu"'
Autor:
Nebojsa Skorupan, Cody J. Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I. Ahmad, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Guillaume Joe Pegna, Seth M. Steinberg, Shelley S. Kalsi, Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundLMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin (iTox) carrying a Pseudomonas exotoxin A payload that has shown promise against solid tumors, however, efficacy is limited by the development of neutralizing anti-drug antibod
Externí odkaz:
https://doaj.org/article/7b50e02d4e8d4d54b44bd8cfb4b2d620
Autor:
Guillaume Joe Pegna, Min‐Jung Lee, Cody J. Peer, Mehwish I. Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4236-4249 (2023)
Abstract LMB‐100 is a novel immune‐conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB‐100 ± nab‐paclitaxel. Participant blo
Externí odkaz:
https://doaj.org/article/b0426dc9f76e4ee5ac65fe73a10166c9
Autor:
Yunkai Yu, Dominic Esposito, Zhigang Kang, Jianming Lu, Alan T. Remaley, Valeria De Giorgi, Leonard N. Chen, Kamille West, Liang Cao
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Several variants of SARS-CoV-2 have emerged. Those with mutations in the angiotensin-converting enzyme (ACE2) receptor binding domain (RBD) are associated with increased transmission and severity. In this study, we developed both antibody qu
Externí odkaz:
https://doaj.org/article/61171dc33999416282cf9da1e350fd76
Autor:
Xianyu Zhang, Yunkai Yu, Cody J. Peer, Rebekah Landsman, Nebojsa Skorupan, Liang Cao, Christine Alewine
Publikováno v:
Translational Oncology, Vol 21, Iss , Pp 101440- (2022)
Mesothelin (MSLN) is overexpressed by many cancers, including pancreatic ductal adenocarcinoma (PDAC) and has consequently become a target for anti-cancer therapeutics. Mature, membrane bound MSLN is cleaved by proteases, releasing a shed form that t
Externí odkaz:
https://doaj.org/article/9fd8099ceea94d9b9d4c45b0e8b8941a
Autor:
Skorupan, Nebojsa, Peer, Cody J., Xianyu Zhang, Hyoyoung Choo-Wosoba, Ahmad, Mehwish I., Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Pegna, Guillaume Joe, Steinberg, Seth M., Kalsi, Shelley S., Liang Cao, Figg, William D., Trepel, Jane B., Pastan, Ira, FitzGerald, David, Alewine, Christine
Publikováno v:
Frontiers in Oncology; 2024, p01-12, 12p
Publikováno v:
Catalysis Science & Technology. 13:1437-1447
Reducing the bidentate ether species formed from the chemisorption between PO and acid sites in the TS/H2O2 system is key to achieving stable operation of the HPPO process.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::468fc321f212283b94c9ed50c5dd6df3
https://doi.org/10.1039/d2cy01814d
https://doi.org/10.1039/d2cy01814d
Publikováno v:
Physical Chemistry Chemical Physics. 25:12220-12230
A protic solvent (ROH/H2O) acts as a mediator to promote the proton transfer during H2O2 activation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a761d3d8db425f9b3d11694f9f6f938
https://doi.org/10.1039/d2cp05483c
https://doi.org/10.1039/d2cp05483c
Publikováno v:
Catalysis Today. :258-266
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c0a79c326837b81d44d72df70ddfb2a
https://doi.org/10.1016/j.cattod.2022.04.034
https://doi.org/10.1016/j.cattod.2022.04.034
Reaction Pathways in the Oxidation Decomposition of Hydroxylamine over a Titanosilicates/H2O2 System
Publikováno v:
The Journal of Physical Chemistry C. 126:19178-19187
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2698abf452d0454ae64d6b82bc658907
https://doi.org/10.1021/acs.jpcc.2c06193
https://doi.org/10.1021/acs.jpcc.2c06193
Systemic immune changes accompany combination treatment with immunotoxin LMB ‐100 and nab‐paclitaxel
Autor:
Guillaume Joe Pegna, Min‐Jung Lee, Cody J. Peer, Mehwish I. Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine
Publikováno v:
Cancer Medicine. 12:4236-4249
LMB-100 is a novel immune-conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB-100 ± nab-paclitaxel. Participant blood samples were a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f266d94506f1f3f0da5b65b19da4697
https://doi.org/10.1002/cam4.5290
https://doi.org/10.1002/cam4.5290